Japan Tissue Engineering Co Ltd banner

Intrinsic Value

The intrinsic value of Japan Tissue Engineering Co Ltd (7774) under the Base Case is 552.84 JPY per share. Compared with the current market price of 730 JPY, the stock appears Overvalued by 24% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

Intrinsic Value
¥552.84
Overvaluation 24%
Intrinsic Value
Price ¥730
J

Japan Tissue Engineering Co Ltd is valued in line with its history. A premium of this size has been typical over the past 5 years.

Monitor Japan Tissue Engineering Co Ltd
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value ¥442.27
Get notified when the price drops into your buy zone
Current Price ¥730
Intrinsic Value ¥552.84
Margin of Safety 20% ¥442.27
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Alternatives to Japan Tissue Engineering Co Ltd

Fundamental Analysis

What Japan Tissue Engineering Does

Biotechnology Health Care

Japan Tissue Engineering makes regenerative medicine products, especially lab-grown skin and other tissue-engineered treatments used in hospitals. It also develops the cell-culture and manufacturing processes needed to grow living tissue safely for medical use. In simple terms, it turns a patient’s own cells or donor cells into medical products that help repair damaged tissue.

Headquarters
Japan JP
Employees
204
IPO date
Dec 21, 2007
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
Japan Tissue Engineering Co Ltd

Wall St Price Targets

Capital Returns

Competitive Landscape

What is the Intrinsic Value of one Japan Tissue Engineering Co Ltd stock?

The intrinsic value for Japan Tissue Engineering Co Ltd (7774) under the Base Case is 552.84 JPY.

Is Japan Tissue Engineering Co Ltd stock undervalued or overvalued?

Compared with the current market price of 730 JPY, the stock appears Overvalued by 24% .

Back to Top